Mumps Vaccine (MumpsVax) Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

This Mumps Vaccine (MumpsVax) market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.

The growth observed during the historical period can be linked to a rise in pediatric vaccination rates, a boost in global health initiatives, greater public confidence in vaccines, increased awareness of travel-related health, and more widespread immunization campaigns.

In the forecast period, growth is expected due to the increasing prevalence of vaccine-preventable diseases, heightened awareness of adult vaccination, growing health consciousness, expanding immunization programs, and more international health efforts. Key trends for the forecast period include personalized vaccination strategies, the integration of digital health technologies, improved surveillance systems, increased research and development for adult vaccinations, and the use of artificial intelligence.

The rising prevalence of infectious diseases is expected to propel the growth of the mumps vaccine (mumpsvax) market going forward. Infectious diseases are illnesses caused by pathogenic microorganisms, such as viruses, bacteria, fungi, or parasites, which can be transmitted between individuals or through contaminated environments. Factors such as urbanization, climate change, globalization, and changes in human demographics and behavior contribute to the increased transmission and emergence of pathogens. Mumpsvax is primarily used to prevent mumps, an infectious disease caused by the mumps virus, often included in the MMR (measles, mumps, rubella) vaccination. For instance, in August 2024, the UK Health Security Agency reported a rise in measles cases, with the West Midlands region having the highest number of cases in 2023, contributing to a rise in mumps vaccinations as part of the broader infectious disease prevention efforts. Therefore, the rise in infectious diseases drives the mumps vaccine (mumpsvax) market.

Rising healthcare expenditure is expected to propel the growth of the mumps vaccine (mumpsvax) market. Healthcare expenditure refers to the total amount spent on health care goods and services, including personal healthcare, preventive services, and public health initiatives aimed at improving health outcomes. Factors like an aging population, chronic diseases, advanced medical technology, and increasing demand for services contribute to the rise in healthcare spending. This increase directly impacts Mumpsvax by improving funding for vaccination programs, thereby boosting vaccine accessibility and leading to higher immunization rates. For instance, in May 2024, the UK Office for National Statistics reported a 5.6% increase in total healthcare expenditure from 2022 to 2023, reinforcing funding for vaccinations and improving public health outcomes. Therefore, the rise in healthcare expenditure drives the mumps vaccine (mumpsvax) market.

The increasing number of clinical trials is expected to propel the growth of the mumps vaccine (mumpsvax) market. Clinical trials are essential in advancing the understanding and treatment of various health conditions, including infectious diseases like mumps. Mumpsvax serves as a reliable tool for evaluating vaccine efficacy, safety, and immune response, particularly in trials focused on pediatric immunization and viral infections. For instance, in May 2023, Xtalks reported that over 452,000 clinical trials were registered globally, a significant increase from previous years. This growing number of clinical trials contributes to the continued development and assessment of vaccines like Mumpsvax. Therefore, the increase in clinical trials drives the mumps vaccine (mumpsvax) market.

Major players operating in the mumps vaccine (mumpsvax) market are Merck & Co. Inc.; GlaxoSmithKline plc.

North America was the largest region in the mumps vaccine (mumpsvax) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in mumps vaccine (mumpsvax) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the mumps vaccine (mumpsvax) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The mumps vaccine (MumpsVax) is a live attenuated vaccine that protects against mumps by using the Jeryl Lynn strain of the virus. It is typically administered in two doses and is commonly combined with the MMR (measles, mumps, rubella) vaccine, offering more than 95% protection against mumps. Although standalone production of the mumps vaccine has been discontinued, it continues to play a vital role in public health initiatives to control mumps outbreaks, significantly reducing the incidence of the disease in vaccinated populations.

Mumps vaccine (MumpsVax) is available in several product types, including monovalent, combinational, divalent, trivalent, and others. Monovalent vaccines specifically target mumps, while combinational vaccines provide protection against multiple diseases, such as measles and rubella, in a single shot. The vaccine is used by both pediatric and adult age groups, with distribution through hospital pharmacies, drug stores, and retail pharmacies. It is utilized by a range of end-users, including pediatric clinics, hospitals, non-governmental organizations (NGOs), and others.

The mumps vaccine (mumpsvax) market research report is one of a series of new reports that provides mumps vaccine (mumpsvax) market statistics, including mumps vaccine (mumpsvax) industry global market size, regional shares, competitors with a mumps vaccine (mumpsvax) market share, detailed mumps vaccine (mumpsvax) market segments, market trends and opportunities, and any further data you may need to thrive in the mumps vaccine (mumpsvax) industry. This mumps vaccine (mumpsvax) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The mumps vaccine (mumpsvax) market consists of sales of mumps vaccines, including both standalone mumps vaccines and combination vaccines. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.